Phase 3 Sleep Disorders Trial, Recruiting NCT07571109 Sponsor: Novo Nordisk A/S Condition: Sleep Disorders
Back to Sleep Disorders

Phase 3 Sleep Disorders Trial, Recruiting

NCT07571109
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who were assigned male or female at birth
  • People who are 18 years of age or older at the time of signing the consent form
  • People who have previously been diagnosed with moderate-to-severe obstructive sleep apnea (a condition where breathing repeatedly stops during sleep), confirmed by a sleep study or approved testing method, with a certain level of breathing disruptions per hour (confirm with trial site for exact threshold)

Who may not be able to join:

  • People whose blood sugar control levels (measured by a specific blood test called HbA1c) are at or above a certain threshold at the screening appointment, as measured by the trial laboratory
  • People who have a personal history of type 1 or type 2 diabetes, either as reported by them or recorded in their medical records
  • People who have had, or have planned, surgery for sleep apnea within the 90 days before screening — this includes certain nose, throat, or ear surgeries such as tonsil or adenoid removal
  • People who have significant structural differences in the face or skull that may affect breathing
  • People who have previously been treated with a class of medications known as GLP-1 receptor agonists, dual GLP-1/GIP receptor agonists, or similar GLP-1-based treatments, or a medication type called amylin analogues, before the screening appointment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Transparency dept. 2834, Novo Nordisk A/S

Phone: (+1) 866-867-7178

Australian sites

Woolcock Institute, Macquarie Park, New South Wales
University of Sunshine Coast - Vitality Village, Birtinya, Queensland
Mater Research - RIO Clinical Trials Unit, South Brisbane, Queensland
Nightingale Research, Adelaide, South Australia
University of Western Australia - Centre for Sleep Science, Crawley, Western Australia

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
5 May 2026
Est. completion
26 June 2028

Where this trial is recruiting

🇦🇺 Australia 🇨🇳 China 🇩🇪 Germany 🇮🇳 India 🇯🇵 Japan 🇵🇱 Poland 🇪🇸 Spain 🇹🇼 Taiwan Turkey (Türkiye) 🇺🇸 United States

5 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Relative change in body weight; Change in apnoea-hypopnoea index (AHI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov